In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s” by Charles Piller Will this affect your life? How?

A paradigm-shifting study shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the ...

A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The plaintiffs ...

Cassava Sciences, a Texas biopharma company, had developed simufilam to treat (and possibly cure) Alzheimer’s disease, the most common form of dementia that afflicts tens of millions of people ...

It is that time of year in Bauchi State, Nigeria, when farmers are busy harvesting cassava tubers, a vital crop in the region. In areas like Yalwan Duguri, Duguri, Pali, and Gwana in the Alkaleri ...

Defendants' statements included, among other things, clear confidence in simufilam's ability to treat Alzheimer's Disease. On November 25, 2024, Cassava released topline results for the first of ...

Medscape Medical News, December 06, 2024 Cassava Shares Sink on Plans to Stop Alzheimer's Drug Studies Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed ...

Alzheimer’s disease affects more than 30m people worldwide, mostly the elderly. After the age of 65, the chance of developing it doubles every five years. By 85, the odds are one in three. Its ...